Keytruda Side Effects Frequency Overview
Keytruda (pembrolizumab), a PD-1 inhibitor, has side effects tied to immune activation, with common ones like fatigue (up to 40-50% of patients), rash (20-30%), diarrhea (15-25%), and nausea (15-20%) in clinical trials across cancers like melanoma and NSCLC.[1] Serious immune-related adverse events (irAEs), such as pneumonitis (3-5%), colitis (1-2%), and endocrinopathies (10-15%), occur less often but can be severe, often requiring steroids.[2]
How Keytruda Compares to Opdivo (Nivolumab)
Opdivo, another PD-1 inhibitor from Bristol Myers Squibb, shows similar profiles: fatigue (30-40%), rash (15-25%), and diarrhea (15-20%). Head-to-head in CheckMate 067 (melanoma), any-grade irAEs were 82% for nivolumab vs. 77% for Keytruda combos, with grade 3-4 events at 21% vs. 19%.[3] Pneumonitis rates are comparable (4% Opdivo vs. 3-5% Keytruda), though Keytruda may edge higher in thyroid issues (15% vs. 10%).[1][4]
Keytruda vs. Other PD-1/L1 Inhibitors Like Tecentriq and Imfinzi
Tecentriq (atezolizumab, PD-L1) reports fatigue (40%), nausea (20%), and lower pneumonitis (1-2%) in lung cancer trials, with overall irAEs at 40-50% vs. Keytruda's 50-60%.[5] Imfinzi (durvalumab, PD-L1) has diarrhea (20%) and fatigue (30%), but hypothyroidism at 10-15% matches Keytruda; severe events like hepatitis are rarer (1% vs. 2%).[6] PD-L1 drugs often have slightly fewer skin and GI issues than PD-1s due to milder T-cell activation.[2]
Comparison with CTLA-4 Inhibitors Like Yervoy
Yervoy (ipilimumab) has higher severe irAE rates—colitis (7-10% grade 3-4), hepatitis (2-5%), and dermatitis (2%)—vs. Keytruda's 15-20% for any severe irAEs. In combos (e.g., Opdivo+Yervoy), grade 3-4 events hit 50-60%, far above Keytruda monotherapy's 10-20%.[3][7] CTLA-4 blockade causes more early, intense toxicity from broader immune stimulation.
Keytruda Combos vs. Monotherapy Frequencies
Keytruda alone: 70-80% any-grade AEs, 15-25% severe.[1] With chemo (e.g., KEYNOTE-189 NSCLC): jumps to 80-90% any-grade, 70% severe, driven by chemo toxicities like anemia (40%).[8] Keytruda+Yervoy-like combos amplify irAEs to 90%+ incidence, with 40-50% severe, per melanoma data.[3]
Why Frequencies Vary Across Trials and Cancers
Rates depend on dose, duration, cancer type, and prior therapy—higher in MSI-high tumors (irAEs 60-70%) vs. NSCLC (40-50%).[2] Real-world data (e.g., from 10,000+ patients) confirm trial patterns but note underreporting of mild events.[9] No direct head-to-head exceeds combos in KEYNOTE trials; meta-analyses show PD-1s like Keytruda have 10-20% lower severe irAEs than CTLA-4 but similar to other PD-1/L1s.[10]
[1] Keytruda Prescribing Information, Merck, merck.com
[2] NEJM, "Pembrolizumab irAEs," 2018
[3] CheckMate 067, NEJM, 2015/2021 updates
[4] Opdivo Prescribing Information, BMS, bms.com
[5] Tecentriq Prescribing Information, Genentech, gene.com
[6] Imfinzi Prescribing Information, AstraZeneca, az.com
[7] Yervoy Prescribing Information, BMS
[8] KEYNOTE-189, NEJM, 2018
[9] JCO, "Real-world Keytruda safety," 2022
[10] Lancet Oncology, "PD-1 vs. CTLA-4 meta-analysis," 2020